Patients with loco-regional NSCLC planned for curative treatment with chemoradiotherapy will be invited to participate in a prospective study; besides routine treatment, the patients will be followed with an ECG and cardiac MR for at least two years after radiotherapy treatment.
Age ≥ 18 Years
Inoperable and histologically/cytologically verified NSCLC.
Planned treatment with curative intent.
Capable of completing study procedures ECG and Cardiac MR.
Vulnerable patients.
Patients with operable devices as pacemaker/ICD and cochlear implant or other conditions where MR scan is contraindicated.
Claustrophobia.
Patients with locally advanced non-small-cell lung cancer will be included at the department of oncology at Odense University Hospital.
Cohort
Prospective
Chemoradiotherapy
Other interventionCardiac Magnetic Resonance scan and ECG
Overall survival
All cause mortality
Change in Left Ventricular Ejection Fraction
Change from baseline, evaluated by cardiac MR
Number of participants with treatment related adverse events and cardiac disease after radiotherapy as assesed by CTCAE v4.0.
Assesed by patient interview and review of medical record.
Cardiovascular specific mortality
Assesed by patient interview and review of medical record
Late enhacment
Evaluated by cardiac MR.
LVEDV changes
Left ventricular enddiastolic change in cMR
LVESV changes
Left ventricular endsystolic change in cMR
LV mass in gram
Left ventricular mass in gram.
Click on the lead sponsor to view all of their trials.
